Privi Speciality Chemicals Limited — PPTs, 10-02-2026: Investor Presentation

Privi Speciality Chemicals reported strong Q3 FY26 results with consolidated revenue up 24% YoY to Rs 611.15 Cr and Profit After Tax (PAT) surging 76% YoY to Rs 77.99 Cr. For the nine months, revenue also grew 24% YoY to Rs 1,857.23 Cr, with PAT jumping 94% YoY to Rs 233.84 Cr. Improved EBITDA margins were driven by operational efficiency, value-added products, and state incentives.

The company is marching towards its vision of Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA in 3-4 years, supported by a Rs 1,200 Cr CAPEX plan for capacity expansion and new speciality product additions. Strategic initiatives include leveraging green chemistry, biotechnology, and consolidating operations through amalgamation to drive efficiency and unlock synergies.

The amalgamation of Privi Fine Sciences and Privi Biotechnologies is progressing. The joint venture, PRIGIV, achieved positive EBITDA in Q3. Givaudan will provide a Rs 150 Cr interest-free trade advance, and both partners will infuse Rs 50 Cr equity for PRIGIV's expansion. Management is confident in achieving the 5k:1k vision, emphasizing innovation and sustainability. They anticipate sustained EBITDA margins above 20%.